Results 61 to 70 of about 39,252 (190)

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency

Viruses, 2014
Both the presence of latently infected cells and cell-to-cell viral transmission are means whereby HIV can partially evade the inhibitory activities of antiretroviral drugs.
Sophie M. Bastarache, Thibault Mesplède, Daniel A. Donahue, Richard D. Sloan, Mark A. Wainberg   +4 more
doaj   +1 more source

Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors

Viruses, 2020
The process of viral integration into the host genome is an essential step of the HIV-1 life cycle. The viral integrase (IN) enzyme catalyzes integration. IN is an ideal therapeutic enzyme targeted by several drugs; raltegravir (RAL), elvitegravir (EVG),
Darren Isaacs, Sello Given Mikasi, Adetayo Emmanuel Obasa, George Mondinde Ikomey, Sergey Shityakov, Ruben Cloete, Graeme Brendon Jacobs   +6 more
doaj   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, EarlyView.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Structural Insights on Retroviral DNA Integration: Learning from Foamy Viruses

Viruses, 2019
Foamy viruses (FV) are retroviruses belonging to the Spumaretrovirinae subfamily. They are non-pathogenic viruses endemic in several mammalian hosts like non-human primates, felines, bovines, and equines.
Ga-Eun Lee, Eric Mauro, Vincent Parissi, Cha-Gyun Shin, Paul Lesbats   +4 more
doaj   +1 more source

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, EarlyView.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source

Perinatal and early infant outcomes after first‐versus second‐generation integrase strand transfer inhibitor use in pregnancy

HIV Medicine, EarlyView.
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are first‐line antiretroviral medications used in pregnancy. Pre‐clinical research suggests adverse effects in human stem cells associated with second‐ versus first‐generation INSTIs.
Rosa Balleny, Jeffrey Man Hay Wong, Terry Lee, Ari Bitnun, Isabelle Boucoiran, Jason Brophy, Jeannette Comeau, Fatima Kakkar, Athena McConnell, Laura Sauvé, Joel Singer, Alena Tse‐Chang, Deborah Money   +12 more
wiley   +1 more source

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors

eLife, 2019
Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a promising new class of antiretroviral agents that disrupt proper viral maturation by inducing hyper-multimerization of IN.
Pratibha C Koneru, Ashwanth C Francis, Nanjie Deng, Stephanie V Rebensburg, Ashley C Hoyte, Jared Lindenberger, Daniel Adu-Ampratwum, Ross C Larue, Michael F Wempe, Alan N Engelman, Dmitry Lyumkis, James R Fuchs, Ronald M Levy, Gregory B Melikyan, Mamuka Kvaratskhelia   +14 more
doaj   +1 more source

Calibration and discrimination ability of the Dat'AIDS score in people living with HIV aged 70 years and older from the Dat'AIDS cohort

HIV Medicine, EarlyView.
Abstract Objective The Dat'AIDS score was developed to predict 5‐year mortality risk in people living with HIV aged 60 and older. However, its validity in people living with HIV aged 70 years and older needed confirmation. Methods This was a multicentre prospective cohort study in the Dat'AIDS French cohort.
Abeo Mousse, Clotilde Allavena, Amandine Gagneux‐Brunon, François Raffi, Laurent Hocqueloux, Claire Genet, Madeline Pascard, Damien Jolly, Firouzé Bani‐Sadr, Lukshe Kanagaratnam, Maxime Hentzien, and The Dat'AIDS Study Group, C. Chirouze, C. Drobacheff‐Thiébaut, A. Foltzer, K. Bouiller, L. Hustache‐Mathieu, Q. Lepiller, F. Bozon, O Babre, AS. Brunel, P. Muret, E. Chevalier, C. Jacomet, H. Laurichesse, O. Lesens, M. Vidal, N. Mrozek, C. Aumeran, O. Baud, V. Corbin, E. Goncalvez, A Mirand, A brebion, C Henquell, I. Lamaury, I. Fabre, E. Curlier, R. Ouissa, C. Herrmann‐Storck, B. Tressieres, MC. Receveur, F. Boulard, C. Daniel, C. Clavel, PM. Roger, S. Markowicz, N. Chellum Rungen, D. Merrien, P. Perré, T. Guimard, O. Bollangier, S. Leautez, M. Morrier, L. Laine, D. Boucher, P. Point, L. Cotte, F. Ader, A. Becker, A. Boibieux, C. Brochier, F Brunel‐Dalmas, O. Cannesson, P. Chiarello, C. Chidiac, S. Degroodt, T. Ferry, M. Godinot, J.M. Livrozet, D. Makhloufi, P. Miailhes, T. Perpoint, M. Perry, C. Pouderoux, S. Roux, C. Triffault‐Fillit, F. Valour, C. Charre, V. Icard, J.C. Tardy, M.A. Trabaud, I. Ravaux, A. Ménard, AY. Belkhir, P. Colson, C. Dhiver, A. Madrid, M. Martin‐Degioanni, L. Meddeb, M. Mokhtari, A. Motte, A. Raoux, C. Toméi, H. Tissot‐Dupont, I. Poizot‐Martin, S. Brégigeon, O. Zaegel‐Faucher, V. Obry‐Roguet, H Laroche, M. Orticoni, M.J. Soavi, E. Ressiot, M.J. Ducassou, I. Jaquet, S. Galie, H. Colson, A.S. Ritleng, A. Ivanova, C. Debreux, C. Lions, T Rojas‐Rojas, A. Cabié, S. Abel, J. Bavay, B. Bigeard, O. Cabras, L. Cuzin, R. Dupin de Majoubert, L. Fagour, K. Guitteaud, A. Marquise, F. Najioullah, S. Pierre‐François, J. Pasquier, P. Richard, K. Rome, JM Turmel, C. Varache, N. Atoui, M. Bistoquet, E Delaporte, V. Le Moing, A. Makinson, N. Meftah, C. Merle de Boever, B. Montes, A. Montoya Ferrer, E. Tuaillon, J. Reynes, B. Lefèvre, E. Jeanmaire, S. Hénard, E. Frentiu, A. Charmillon, A. Legoff, N. Tissot, M. André, L. Boyer, MP. Bouillon, M. Delestan, F. Goehringer, S. Bevilacqua, C. Rabaud, T. May, F. Raffi, C. Allavena, E. Billaud, C. Biron, B. Bonnet, S. Bouchez, D. Boutoille, C. Brunet‐Cartier, C. Deschanvres, B.J. Gaborit, M. Grégoire, O. Grossi, T. Jovelin, M. Lefebvre, P. Le Turnier, R. Lecomte, P. Morineau, V. Reliquet, S. Sécher, M. Cavellec, E. Paredes, A. Soria, V. Ferré, E. André‐Garnier, A. Rodallec, P. Pugliese, S. Breaud, C. Ceppi, D. Chirio, E. Cua, P. Dellamonica, E. Demonchy, A. De Monte, J. Durant, C. Etienne, S. Ferrando, R. Garraffo, C. Michelangeli, V. Mondain, A. Naqvi, N. Oran, I. Perbost, M. Carles, C. Klotz, A. Maka, C. Pradier, B. Prouvost‐Keller, K. Risso, V. Rio, E. Rosenthal, I. Touitou, S. Wehrlen‐Pugliese, G. Zouzou, L. Hocqueloux, C.Mille. T. Prazuck, C. Gubavu, A. Sève, G. Béraud, V. Legros, V. Avettand‐Fènoël, A. Cheret, C. Goujard, Y. Quertainmont, E. Teicher, N. Lerolle, S. Jaureguiberry, R. Colarino, O. Deradji, A. Castro, A. Barrail‐Tran, Y. Yazdanpanah, R. Landman, V. Joly, J. Ghosn, C. Rioux, S. Lariven, A. Gervais, FX. Lescure, S. Matheron, F. Louni, Z. Julia, S. Le GAC C. Charpentier, D. Descamps, G. Peytavin, C. Duvivier, C. Aguilar, F. Alby‐Laurent, K. Amazzough, G. Benabdelmoumen, P. Bossi, G. Cessot, C. Charlier, P.H. Consigny, K. Jidar, E. Lafont, F. Lanternier, J. Leporrier, O. Lortholary, C. Louisin, J. Lourenco, P. Parize, B. Pilmis, C. Rouzaud, F. Touam, MA. Valantin, R. Tubiana, R. Agher, S. Seang, L. Schneider, R. PaLich, C. Blanc, C. Katlama, F. Bani‐Sadr, M. Hentzien, A. Brunet, D. Lambert, C. Strady, M. Moutel, M. Petithomme‐Nanrocki, V. Greigert, I. Kmiec, H. Marty, V. Brodard, C. Arvieux, P. Tattevin, M. Revest, F. Souala, M. Baldeyrou, S. Patrat‐Delon, J.M. Chapplain, F. Benezit, M. Dupont, M. Poinot, A. Maillard, C. Pronier, F. Lemaitre, C. Morlat, M. Poisson‐Vannier, T. Jovelin, JP. Sinteff, A. Gagneux‐Brunon, E. Botelho‐Nevers, A. Frésard, V. Ronat, F. Lucht, D. Rey, P. Fischer, M. Partisani, C. Cheneau, C. Mélounou, C. Bernard‐Henry, E. de Mautort, S. Fafi‐Kremer, P. Delobel, M. Alvarez, N. Biezunski, A. Debard, C. Delpierre, G. Gaube, P. Lansalot, L. Lelièvre, M. Marcel, G. Martin‐Blondel, M. Piffaut, L. Porte, K. Saune, O. Robineau, F. Ajana, E. Aïssi, I. Alcaraz, E. Alidjinou, V. Baclet, L. Bocket, A. Boucher, M. Digumber, T. Huleux, B. Lafon‐Desmurs, A. Meybeck, M. Pradier, M. Tetart, P. Thill, N. Viget, M. Valette   +337 more
wiley   +1 more source

Mitigating genetic instability caused by the excision activity of the phiC31 integrase in Streptomyces

Applied and Environmental Microbiology
Over the past three decades, the integrase (Int) from Streptomyces phage phiC31 has become a valuable genome engineering tool across various species. phiC31 Int was thought to mediate unidirectional site-specific integration (attP × attB to attL and attR)
Yadan Duan, Zhangliang Liu, Xiaofang Huang, Lu Xu, Xianxue Wang, Hao Liu, Zhoujie Xie   +6 more
doaj   +1 more source